Skip to content

Virtual Reality Training for Aggression Control in a Dutch prison-based population - a randomized controlled trial.

Virtual Reality Training for Aggression Control in a Dutch prison-based population - a randomized controlled trial. - VR-TRAC

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON49888
Enrollment
128
Registered
2022-04-25
Start date
2023-04-18
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Emotie regulatie problematiek: agressie Aggression

Interventions

The protocol that will be used in this study is based on the protocol that has been developed by Klein Tuente et al. (2018). In our pilot (METc 2019/381, registered under file number NL71610.042.19)

Sponsors

Universitair Medisch Centrum Groningen
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Detainees who are imprisoned in P.I. Vught, The Netherlands, for at least 20 weeks. - Detainees with aggression regulation problems in the last month, as measured with the AQ (a minimum score of 70). - Minimum age of 18 years old.

Exclusion criteria

Exclusion criteria: - SCIL score of 14 or lower. - Acute suicidal behavior or current psychotic episode. - Insufficient command and understanding of the Dutch language. - Photosensitive epileptic seizure in the past year. - An estimated stay of 5 months or shorter - Following other treatments with the aim to control aggression.

Design outcomes

Primary

MeasureTime frame
The primary objective of this randomized controlled trial is to investigate the effect of the VR-TRAC on aggression in a prison-based population. Firstly, through staff observation, secondly, through self-report measurements and lastly, with scripted role-plays. The primary outcome will be measured through a self-report measurement, the *Aggression Questionnaire (AQ)*, wich measures four different types of aggression.

Secondary

MeasureTime frame
Self-report questionnaires Individual changes are measured through self-report measurements. Self-report will consist of questionnaires that are filled in by participants with help of the research assistant, measuring different types of aggression (overt and covert), anger, impulsiveness, and emotion regulation. The questionnaires will be scored on three different moments during the study: before the treatment, at the end of the treatment, and two- months after the treatment ended. Five questionnaires will be used as secondary study parameters: - The Difficulties in emotion regulation (DERS) consists of 36 items measuring difficulties in emotion regulation. - The Novaco Anger Scale and Provocation Inventory (NAS-PI) consists of two parts, The NAS part contains 48 questions and measures three factors; cognitive, arousal and behavior. - The Reactive-Proactive Questionnaire (RPQ) consists of two 23 items (11 items on reactive aggression and 12 items on proactive aggression). - The Short Anger Measure (SAM) is a self-report and consists of 12 items measuring angry feelings and aggressive impulses over the last week. - The Barratt Impulsiveness Scale (BIS-11) measures the personality/behavioral construct of impulsiveness. One questionnaire will measure the experience of presence in VR (I group Presence Questionnaire). Staff observation For the staff observation, the Observation Scale for Aggressive Behaviour (OSAB) will be used (Hornsveld, Nijman, Hollin, & Kraaimaat, 2007). The OSAB consists of 40 items measuring emotions/mood, aggressive behavior, the reason for the aggressive behavior, sanction for the patient, and socially competent behavior. Scripted role-plays To measure the effectiveness of the skills trained in the VR-TRAC, scripted role-play assessments will be conducted. The role-play will be scheduled at two-time points. For the treatment group, this will be before the training will start and once after the treatment has ended. F

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)